Adamis Pharmaceuticals says that it has received additional US and European patents for the Taper dry powder inhaler, which the company acquired from 3M Drug Delivery Systems in 2013. In January 2015, Adamis announced that it had received US and Japanese patents for the Taper DPI.
The company says that it had received a notice of allowance from the USPTO for Patent Application No. 14/622,617, which describes the device and its components, including powder storage cassettes. The European patent, (EP1996173 “Powder Filling Processes”) covers filling of the powder onto the 3MDDS microcarrier tape.
Adamis is developing its APC-5000 fluticasone/salmeterol DPI using the Taper device and says that it plans to manufacture a sufficient number of the devices for Phase 3 testing of the product in 2017. The company previously announced positive results from a Phase 1 PK study of APC-5000 in March 2015.
Read the Adamis Pharmaceuticals press release.
